1. |
Clancy TE. Surgery for pancreatic cancer. Hematol Oncol Clin North Am, 2015, 29(4):701-716.
|
2. |
彭承宏.重视胰腺癌术前手术可切除性评估.外科理论与实践, 2007, 12(3):196-198.
|
3. |
Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer:expert consensus statement. Ann Surg Oncol, 2009, 16(7):1727-1733.
|
4. |
中华医学会外科学分会胰腺外科学组.胰腺癌诊治指南(2014).中华普通外科杂志, 2015, 30(1):73-79.
|
5. |
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer:the CONKO-001 randomized trial. JAMA, 2013, 310(14):1473-1481.
|
6. |
Delpero JR, Bachellier P, Regenet N, et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma:a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford), 2014, 16(1):20-33.
|
7. |
Mahipal A, Frakes J, Hoffe S, et al. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol, 2015, 7(10):241-249.
|
8. |
Rückert F, Distler M, Ollmann D, et al. Retrospective analysis of survival after resection of pancreatic renal cell carcinoma metastases. Int J Surg, 2016, 26:64-68.
|
9. |
Butler JR, Ahmad SA, Katz MH, et al. A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford), 2016, 18(4):305-311.
|
10. |
Poruk KE, Gay DZ, Brown K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma:diagnostic and prognostic updates. Curr Mol Med, 2013, 13(3):340-351.
|
11. |
Distler M, Pilarsky E, Kersting S, et al. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas-a retrospective tumor marker prognostic study. Int J Surg, 2013, 11(10):1067-1072.
|
12. |
Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol, 2006, 24(18):2897-2902.
|
13. |
Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol, 2012, 23(7):1713-1722.
|
14. |
Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer:perspective to adjust surgical and perioperative therapy. Ann Surg Oncol, 2013, 20(7):2188-2196.
|
15. |
Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9≥1 000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9):2216-2227.
|
16. |
Liu L, Xu HX, Wang WQ, et al. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Oncotarget, 2016, 7(5):5943-5956.
|
17. |
李宁, 沈世强, 刘建超.血清CA19-9、CA242、CEA及CA125在胰腺癌诊断和预后中的价值.中国普外基础与临床杂志, 2011, 18(3):300-304.
|
18. |
Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template:consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology, 2014, 146(1):291-304.e1.
|
19. |
Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer:need for standardization and methods for optimal clinical trial design. Ann Surg Oncol, 2013, 20(8):2787-2795.
|